Pipeline

January 15, 2018

Company	Drug/Device	Medical Condition	Status
Chimerix	brincidofovir	adenovirus infection related to pediatric transplant	Phase I trials initiated in 141 subjects in the U.S. and Europe
Oncolix	Prolanta	advanced ovarian cancer	Phase I trials initiated
Immix Biopharma	IMX-110	advanced Solid Tumors	Phase I/IIa trials planned
Aptevo Therapeutics	otlertuzumab	peripheral T-cell lymphoma	Phase II trials initiated enrolling 24 subjects
Novaliq	NOV03	dry eye disease	Phase II trials initiated
Akcea Therapeutics	AKCEA-APOCIII-LRx	hypertriglyceridemia, established cardiovascular disease	Phase IIb trials initiated
CymaBay Therapeutics	seladelpar	primary biliary cholangitis	Phase II/III trials initiated
Minoryx Therapeutics	MIN-102	adrenomyeloneuropathy	Phase II/III trials initiated globally
Semnur Pharmaceuticals	SP-102	lumbar radicular pain/sciatica	Phase III trials initiated enrolling 400 subjects in the U.S.
Semnur Pharmaceuticals	SP-102	lumbar radicular pain/sciatica	Fast Track designation granted by the FDA
Avadel Pharma	FT 218	narcolepsy	Orphan Drug designation granted by the FDA
Spruce Biosciences	SPR001	congenital adrenal hyperplasia	Orphan Drug designation granted by the EMA
AbbVie	upadacitinib (ABT-494)	moderate to severe atopic dermatitis	Breakthrough Therapy designation granted by the FDA
Global Blood Therapeutics	voxelotor	sickle cell disease	Breakthrough Therapy designation granted by the FDA
Amgen	Xgeva (denosumab)	prevention of skeletal-related events in patients with multiple myeloma	FDA expanded approval